


PHARMACEUTICAL 2022

Olimero

ALIMERA SCIENCES INC Rank 131 of 466





PHARMACEUTICAL 2022

ALIMERA SCIENCES INC Rank 131 of 466



The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 132% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 130% points above the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 42,160 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 10,897 |
| Liabilities, Current | 12,592 |
| Liabilities, Non-Current | 0 |
| Other Assets | 2,680 |
| Other Compr. Net Income | -1,296 |
| Other Expenses | 38,529 |
| Other Liabilities | 0 |
| Other Net Income | 1,680 |
| Other Revenues | 59,029 |
| Property and Equipment | 2,783 |
| Research and Development | 13,778 |
| Selling, General and Administrative Expense | 12,774 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 58,520 |
| Liabilities | 12,592 |
| Expenses | 65,081 |
| Revenues | 59,029 |
| Stockholders Equity | 45,928 |
| Net Income | -4,372 |
| Comprehensive Net Income | -5,020 |
| Economic Capital Ratio | 208% |

